Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

Empiric triple therapy for Helicobacter pylori should be abandoned when clarithromycin resistance rate is >15–20%. Optimisation of triple therapy (high‐dose acid suppression and 14‐day duration) can increase eradication rates by 10%.

[1]  J. Gisbert,et al.  Su1172 Non-Bismuth Quadruple (Concomitant) Therapy for Eradication of H. pylori: Standard vs. Optimized (14-Day, High-Dose PPI) Regimen , 2014 .

[2]  K. Dunbar,et al.  Su1194 Sequential Therapy Is Not Better At Eradication of Primary Helicobacter pylori Infection When Compared to Standard Triple Therapy in the United States-a Prospective, Randomized Evaluation in a United States Population , 2014 .

[3]  J. Gisbert,et al.  Su1174 Sequential and Concomitant Treatments in H. pylori Eradication: A Network Meta-Analysis , 2014 .

[4]  F. Mégraud,et al.  Su1165 Meta-Analysis of Sequential vs. Standard Triple Therapy for Helicobacter pylori Eradication: Final Results of a Cochrane Systematic Review , 2014 .

[5]  R. Ge,et al.  The Interaction of a Histidine‐Rich Protein Hpn with the Membrane Mimics: Implications for Pathologic Roles of Hpn in Helicobacter pylori , 2014, Helicobacter.

[6]  D. Graham,et al.  Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  D. Sgouras,et al.  Clinical Evaluation of a Ten‐Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication of Helicobacter pylori in a High Clarithromycin Resistance Area , 2013, Helicobacter.

[8]  A. Mentis,et al.  Is there a nonbismuth quadruple therapy that can reliably overcome bacterial resistance? , 2013, Gastroenterology.

[9]  Nayoung Kim,et al.  Meta‐analysis: Is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? , 2013, Journal of gastroenterology and hepatology.

[10]  H. Miyajima,et al.  Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole , 2013, Alimentary pharmacology & therapeutics.

[11]  Bo-In Lee,et al.  Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis , 2013, Gut and liver.

[12]  C. Scarpignato,et al.  Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy , 2013, BMJ.

[13]  J. Gisbert,et al.  Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. , 2013, Gastroenterology.

[14]  J. Gisbert,et al.  [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. , 2013, Gastroenterologia y hepatologia.

[15]  M. Botero,et al.  Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication , 2013, Alimentary pharmacology & therapeutics.

[16]  J. Gisbert,et al.  Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice , 2013, Gut.

[17]  F. Bermejo,et al.  III Conferencia Española de Consenso sobre la infección por Helicobacter pylori , 2013 .

[18]  N. Ananthakrishnan,et al.  Sequential Therapy Versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: a Systematic Review of Recent Evidence , 2013, Drugs.

[19]  Hsiu‐Po Wang,et al.  Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial , 2013, The Lancet.

[20]  J. Gisbert,et al.  Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of Helicobacter pylori infection , 2012, Alimentary pharmacology & therapeutics.

[21]  H. Szajewska,et al.  Meta‐analysis: sequential therapy for Helicobacter pylori eradication in children , 2012, Alimentary pharmacology & therapeutics.

[22]  J. Gisbert,et al.  Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant Strains , 2012, Helicobacter.

[23]  J. Gisbert,et al.  High‐dose, ten‐day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates , 2012, Alimentary pharmacology & therapeutics.

[24]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.

[25]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[26]  L. Fischbach,et al.  Letter: the ethics of using inferior regimens in H. pylori randomised trials , 2012, Alimentary pharmacology & therapeutics.

[27]  J. Gisbert,et al.  Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori , 2012, Clinical and experimental gastroenterology.

[28]  E. Xirouchakis,et al.  Evaluation of a Four‐drug, Three‐antibiotic, Nonbismuth–containing “Concomitant” Therapy as First‐line Helicobacter pylori Eradication Regimen in Greece , 2012, Helicobacter.

[29]  J. Gisbert,et al.  Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough , 2011, Alimentary pharmacology & therapeutics.

[30]  P. Malfertheiner,et al.  Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial , 2011, The Lancet.

[31]  D. Graham,et al.  Helicobacter pylori treatment in the era of increasing antibiotic resistance , 2010, Gut.

[32]  N. Vakil,et al.  Sequential Therapy or Triple Therapy for Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults and Children , 2009, The American Journal of Gastroenterology.

[33]  R. Hunt,et al.  Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection , 2009, Journal of gastroenterology and hepatology.

[34]  D. Graham,et al.  Meta‐analysis: Four‐Drug, Three‐Antibiotic, Non‐bismuth‐Containing “Concomitant Therapy” Versus Triple Therapy for Helicobacter pylori Eradication , 2009, Helicobacter.

[35]  S. Xiao,et al.  Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta‐analysis , 2009, Journal of clinical pharmacy and therapeutics.

[36]  C. Hornung,et al.  Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment , 2008, Annals of Internal Medicine.

[37]  W. Chey,et al.  American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection , 2007, The American Journal of Gastroenterology.

[38]  C. Hassan,et al.  Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication , 2007, Annals of Internal Medicine.

[39]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[40]  C. Hassan,et al.  Standard triple and sequential therapies for Helicobacter pylori eradication: an update. , 2013, European journal of internal medicine.

[41]  J. Gisbert,et al.  [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. , 2013, Gastroenterologia y hepatologia.

[42]  J. Gisbert,et al.  [III Spanish Consensus Conference on Helicobacter pylori infection]. , 2013, Gastroenterologia y hepatologia.

[43]  J. Gisbert.  Is culture necessary before first-line treatment for Helicobacter pylori infection? , 2011, Internal medicine.